Literature DB >> 21461913

Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy.

Andrés Duarte-Rojo1, José Estradas, Roberto Hernández-Ramos, Sergio Ponce-de-León, Juan Córdoba, Aldo Torre.   

Abstract

BACKGROUND: The psychometric hepatic encephalopathy score (PHES) is a battery of neuropsychological tests used in the diagnosis of minimal hepatic encephalopathy (MHE). AIM: The aim of this study was to construct and validate a dataset of normal values for the PHES.
METHODS: Volunteers and patients with cirrhosis with and without low-grade overt hepatic encephalopathy (OHE) were enrolled. All subjects completed the PHES battery, and possible modifying factors were assessed. Formulas to predict expected scores in cirrhotics were constructed, and MHE was diagnosed whenever a deviation of <-4 SDs occurred across the five tests.
RESULTS: Among the 743 volunteers, age and years of education influenced the scores of all tests. Eighty-four patients with cirrhosis lacked evidence of OHE, whereas 20 had OHE: median PHES were -1 [0 to -3] and -9 [-6.5 to -11.8] (P < 0.001), respectively. Thirteen of the 84 patients (15%) with cirrhosis but without OHE had MHE. Patients with MHE were older and less educated than those without MHE (61 ± 8 and 52 ± 10 years old, P = 0.003; 7 ± 4 and 12 ± 5 years education, P = 0.002), whereas liver function was not different (MELD, 8 ± 5 and 8 ± 5). A very strong correlation between these norms and those derived from Spain was observed (r = 0.964, P < 0.001).
CONCLUSIONS: PHES performance was mostly influenced by age and education, and expected results in cirrhotics need to be adjusted for these factors. Our validation of Mexican norms for PHES (PHES-Mex) establishes a practical method for assessing MHE and contributes to international attempts to standardize diagnostic protocols for MHE.

Entities:  

Mesh:

Year:  2011        PMID: 21461913     DOI: 10.1007/s10620-011-1684-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  [Normality tables in the Spanish population for psychometric tests used in the diagnosis of minimal hepatic encephalopathy].

Authors:  Manuel Romero Gómez; Juan Córdoba; Rodrigo Jover; Juan del Olmo; Ana Fernández; Montse Flavià; Luis Compañy; María José Poveda; Vicente Felipo
Journal:  Med Clin (Barc)       Date:  2006-07-15       Impact factor: 1.725

2.  Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study.

Authors:  Piero Amodio; Francesca Campagna; Stefania Olianas; Pamela Iannizzi; Daniela Mapelli; Marco Penzo; Paolo Angeli; Angelo Gatta
Journal:  J Hepatol       Date:  2008-06-02       Impact factor: 25.083

3.  Improving the inhibitory control task to detect minimal hepatic encephalopathy.

Authors:  Piero Amodio; Lorenzo Ridola; Sami Schiff; Sara Montagnese; Chiara Pasquale; Silvia Nardelli; Ilaria Pentassuglio; Maria Trezza; Chiara Marzano; Cristiana Flaiban; Paolo Angeli; Giorgia Cona; Patrizia Bisiacchi; Angelo Gatta; Oliviero Riggio
Journal:  Gastroenterology       Date:  2010-05-11       Impact factor: 22.682

4.  Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy.

Authors:  Oliviero Riggio; Lorenzo Ridola; Chiara Pasquale; Silvia Nardelli; Ilaria Pentassuglio; Federica Moscucci; Manuela Merli
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-15       Impact factor: 11.382

Review 5.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

7.  Development of a clinical hepatic encephalopathy staging scale.

Authors:  M Ortiz; J Córdoba; E Doval; C Jacas; F Pujadas; R Esteban; J Guardia
Journal:  Aliment Pharmacol Ther       Date:  2007-09-15       Impact factor: 8.171

8.  Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.

Authors:  Mariano Malaguarnera; Maria Pia Gargante; Erika Cristaldi; Marco Vacante; Corrado Risino; Lisa Cammalleri; Giovanni Pennisi; Liborio Rampello
Journal:  Dig Dis Sci       Date:  2008-03-21       Impact factor: 3.199

9.  Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.

Authors:  Qing Liu; Zhong Ping Duan; Da Kang Ha; Stig Bengmark; Jelica Kurtovic; Stephen M Riordan
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

Review 10.  Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines.

Authors:  Christopher Randolph; Robin Hilsabeck; Ainobu Kato; Parampreet Kharbanda; Yu-Yuan Li; Daniela Mapelli; Lisa D Ravdin; Manuel Romero-Gomez; Andrea Stracciari; Karin Weissenborn
Journal:  Liver Int       Date:  2009-03-19       Impact factor: 5.828

View more
  25 in total

1.  Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans.

Authors:  Thomas K Burroughs; James B Wade; Michael S Ellwood; Andrew Fagan; Douglas M Heuman; Michael Fuchs; Jasmohan S Bajaj
Journal:  Dig Dis Sci       Date:  2018-01-08       Impact factor: 3.199

Review 2.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

Review 3.  Minimal hepatic encephalopathy.

Authors:  Laura M Stinton; Saumya Jayakumar
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

Review 4.  Diagnosis of minimal hepatic encephalopathy.

Authors:  Karin Weissenborn
Journal:  J Clin Exp Hepatol       Date:  2014-07-31

5.  Abnormal baseline brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy revealed by resting-state functional MRI.

Authors:  Xiao-Fei Lv; Min Ye; Lu-Jun Han; Xue-Lin Zhang; Pei-Qiang Cai; Gui-Hua Jiang; Ying-Wei Qiu; Shi-Jun Qiu; Yao-Pan Wu; Kai Liu; Zhen-Yin Liu; Pei-Hong Wu; Chuan-Miao Xie
Journal:  Metab Brain Dis       Date:  2013-07-09       Impact factor: 3.584

6.  Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy.

Authors:  Andrés Duarte-Rojo; Astrid Ruiz-Margáin; Ricardo U Macias-Rodriguez; Francisco Javier Cubero; José Estradas-Trujillo; Rosa Ma Muñoz-Fuentes; Aldo Torre
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

7.  Severity-specific alterations in CBF, OEF and CMRO2 in cirrhotic patients with hepatic encephalopathy.

Authors:  Gang Zheng; Hanzhang Lu; Wenkui Yu; Song Luo; Ya Liu; Wei Liu; Hui Liu; Long Wu; Lijuan Zheng; Xiang Kong; Long Jiang Zhang; Guang Ming Lu
Journal:  Eur Radiol       Date:  2017-05-18       Impact factor: 5.315

8.  Factors That Affect Results of Psychometric Tests to Identify Patients With Minimal Hepatic Encephalopathy.

Authors:  Maria Camila Pérez-Matos; Z Gordon Jiang; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-15       Impact factor: 11.382

9.  Diagnosis of minimal hepatic encephalopathy in a tertiary care center from eastern Romania: validation of the psychometric hepatic encephalopathy score (PHES).

Authors:  Mircea Alexandru Badea; Vasile Liviu Drug; Mihaela Dranga; Otilia Gavrilescu; Gabriela Stefanescu; Iolanda Popa; Catalina Mihai; Cristina Cijevschi-Prelipcean
Journal:  Metab Brain Dis       Date:  2016-07-27       Impact factor: 3.584

Review 10.  Qualifying and quantifying minimal hepatic encephalopathy.

Authors:  Marsha Y Morgan; Piero Amodio; Nicola A Cook; Clive D Jackson; Gerald Kircheis; Mette M Lauridsen; Sara Montagnese; Sami Schiff; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2015-09-28       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.